Millendo Therapeutics Inc. (MLND) Prices 4.167M Share Common Offering at $6/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Millendo Therapeutics Announces Pricing of Public Offering of Common Stock
December 4, 2019 9:02 PM ESTANN ARBOR, Mich.--(BUSINESS WIRE)-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced the pricing of its underwritten public offering of 4,166,667 shares of its common stock at a public offering price of $6.00 per share, for aggregate gross proceeds of $25.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Millendo. In addition, Millendo has granted the underwriters a 30-day option to purchase up to 625,000 additional shares of common stock at the public offering price, less the underwriting... More
